[Loxapine succinate: a new neuroleptic].

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Loxapine succinate is a neuroleptic compound recently commercialized in the USA.
• Schizophrenia is a chronic mental disorder often requiring long-term treatment.

Purpose of the Study:

• To evaluate the antipsychotic and sedative efficacy of loxapine succinate in chronic schizophrenic patients.
• To compare the therapeutic efficiency of oral versus parenteral administration of loxapine succinate.

Main Methods:

• A study involving 28 patients with chronic schizophrenia, 19 of whom were neuroleptic-resistant.
• Parenteral administration of loxapine succinate was assessed.
• Dosages ranged from 100 to 200 mg daily.
• Oral administration was also evaluated for comparison.

Main Results:

• Parenteral loxapine succinate showed antipsychotic and sedative effects in 26 out of 28 patients.
• The drug was well-tolerated locally and systemically, with mild, primarily vegetative side effects.
• Therapeutic efficiency was found to be superior with the oral form compared to the parenteral route at equivalent dosages.

Conclusions:

• Loxapine succinate is an effective antipsychotic and sedative agent for chronic schizophrenia, even in treatment-resistant patients.
• The oral route of administration offers better therapeutic efficiency than the parenteral route.
• The compound exhibits good tolerance and a favorable side effect profile.